MA39867A - Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive - Google Patents
Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptiveInfo
- Publication number
- MA39867A MA39867A MA039867A MA39867A MA39867A MA 39867 A MA39867 A MA 39867A MA 039867 A MA039867 A MA 039867A MA 39867 A MA39867 A MA 39867A MA 39867 A MA39867 A MA 39867A
- Authority
- MA
- Morocco
- Prior art keywords
- cells
- methods
- cell populations
- isolation
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/04—Cell isolation or sorting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Sustainable Development (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
La présente invention concerne par certains aspects des procédés, des cellules et des compositions pour préparer des cellules et des compositions pour le génie génétique et la thérapie cellulaire. Certains modes de réalisation concernent des procédés de préparation de cellules simplifiées, par exemple pour l'isolement, le traitement, l'incubation, et la manipulation génétique de cellules et de populations de cellules. L'invention concerne également des cellules et des compositions produites par les procédés et des procédés pour les utiliser. Les cellules peuvent comprendre des cellules immunitaires, comme des cellules t, et comprennent généralement une pluralité de populations ou de types de cellules t isolées. Dans certains aspects, les procédés permettent la préparation d'une pluralité de populations de cellules différentes pour une thérapie adoptive avec moins d'étapes et/ou moins de ressources et/ou une manipulation réduite par rapport à d'autres procédés.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983415P | 2014-04-23 | 2014-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39867A true MA39867A (fr) | 2017-03-01 |
Family
ID=53055126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051794A MA51794A (fr) | 2014-04-23 | 2015-04-23 | Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive |
| MA039867A MA39867A (fr) | 2014-04-23 | 2015-04-23 | Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051794A MA51794A (fr) | 2014-04-23 | 2015-04-23 | Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US11400115B2 (fr) |
| EP (4) | EP4450615A3 (fr) |
| JP (5) | JP6759187B2 (fr) |
| KR (3) | KR102447958B1 (fr) |
| CN (3) | CN113046312A (fr) |
| AU (3) | AU2015249554B2 (fr) |
| BR (1) | BR112016024579A2 (fr) |
| CA (1) | CA2946312A1 (fr) |
| DK (1) | DK4219687T3 (fr) |
| ES (2) | ES2995052T3 (fr) |
| FI (1) | FI4219687T3 (fr) |
| IL (5) | IL292038B2 (fr) |
| MA (2) | MA51794A (fr) |
| MX (2) | MX382541B (fr) |
| PH (1) | PH12016502112A1 (fr) |
| PL (1) | PL4219687T3 (fr) |
| PT (1) | PT4219687T (fr) |
| RU (1) | RU2763795C2 (fr) |
| SA (1) | SA516380118B1 (fr) |
| SG (1) | SG11201608862SA (fr) |
| WO (1) | WO2015164675A1 (fr) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045659A1 (fr) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Vecteurs lentiviraux sûrs pour une administration ciblée de multiples molécules thérapeutiques |
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| RS62471B1 (sr) | 2014-04-16 | 2021-11-30 | Juno Therapeutics Gmbh | Metode, kompleti i uređaji za proširenje populacije ćelija |
| IL292038B2 (en) * | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| JP6661544B2 (ja) * | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
| SG11201702191YA (en) * | 2014-09-17 | 2017-04-27 | Univ Johns Hopkins | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| JP6740234B2 (ja) | 2014-11-05 | 2020-08-12 | ジュノー セラピューティクス インコーポレイテッド | 形質導入および細胞プロセシングのための方法 |
| WO2016168595A1 (fr) * | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Procédés pour améliorer l'efficacité et l'expansion de cellules exprimant un récepteur antigénique chimérique |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| EP4339287A3 (fr) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Cellules modifiées et procédés de thérapie |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| CA3009852A1 (fr) * | 2015-12-28 | 2017-07-06 | Novartis Ag | Methodes de production de cellules d'expression de recepteur d'antigene chimerique |
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Hivワクチン接種および免疫療法 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| MA43759A (fr) | 2016-03-16 | 2018-11-28 | Jason Connor | Procédés de conception adaptative d'un régime de traitement et traitements associés |
| WO2017213697A1 (fr) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Système d'administration viral sans intégration et procédés associés à ce dernier |
| CA3028982A1 (fr) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Pre-immunisation et immunotherapie du vih |
| WO2018017882A1 (fr) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Vecteurs viraux pour le traitement de la maladie de parkinson |
| MX2019002765A (es) | 2016-09-12 | 2019-05-09 | Juno Therapeutics Inc | Montajes de bolsa de biorreactor de perfusion. |
| CN110267978A (zh) * | 2016-10-07 | 2019-09-20 | 得克萨斯大学体系董事会 | 用于治疗癌症的表达膜锚定的il-12的t细胞 |
| EP4338799A3 (fr) | 2016-10-18 | 2024-06-05 | Regents of the University of Minnesota | Lymphocytes infiltrant les tumeurs et procédés de thérapie |
| WO2018102761A1 (fr) * | 2016-12-02 | 2018-06-07 | City Of Hope | Procédés de préparation et d'accroissement de lymphocytes t exprimant des récepteurs antigéniques chimériques et d'autres récepteurs |
| WO2018106732A1 (fr) * | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production de cellules modifiées pour une thérapie cellulaire adoptive |
| JP7061125B2 (ja) | 2016-12-16 | 2022-04-27 | ダイアグノロジックス・エルエルシー | 浮力による分離方法およびシステム |
| MX2019010171A (es) | 2017-02-27 | 2019-10-15 | Juno Therapeutics Inc | Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular. |
| CN110913690A (zh) | 2017-03-14 | 2020-03-24 | 朱诺治疗学股份有限公司 | 用于低温储存的方法 |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| CN110709700A (zh) | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| AU2018260380B2 (en) | 2017-04-27 | 2025-02-13 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| IL327498A (en) | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| MA50865A (fr) | 2017-06-07 | 2020-04-15 | Seattle Genetics Inc | Lymphocytes t à fucosylation de surface réduite et procédés de production et d'utilisation de ceux-ci |
| US12559769B2 (en) | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| WO2019011879A1 (fr) | 2017-07-09 | 2019-01-17 | Rainer Henning | Agent thérapeutique pour le traitement du syndrome de fuite capillaire |
| KR20200030593A (ko) * | 2017-07-21 | 2020-03-20 | 버클리 라잇츠, 인크. | 항원 제시 합성 표면, 공유결합으로 관능화된 표면, 활성화된 t 세포, 및 이들의 용도 |
| KR102755437B1 (ko) * | 2017-08-09 | 2025-01-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법 |
| EP4516896A3 (fr) | 2017-08-09 | 2025-05-14 | Juno Therapeutics, Inc. | Procédés et compositions pour préparer des cellules génétiquement modifiées |
| KR102546681B1 (ko) | 2017-09-01 | 2023-06-22 | 론차 콜로그네 게엠베하 | 엔드-투-엔드 세포 요법의 자동화 |
| MA50079A (fr) | 2017-09-07 | 2020-07-15 | Juno Therapeutics Inc | Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire |
| EP3697809A1 (fr) * | 2017-10-20 | 2020-08-26 | Institut Curie | Récepteurs antigéniques chimériques (car) à base de dap10/12 adaptés pour rush |
| WO2019089858A2 (fr) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire |
| CA3080509A1 (fr) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Procede pour la production d'une composition de lymphocytes t |
| JP7357626B2 (ja) | 2017-11-01 | 2023-10-06 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞の治療用組成物を生成するためのプロセス |
| US20200330983A1 (en) | 2017-11-10 | 2020-10-22 | Juno Therapeutics, Inc. | Closed-system cryogenic vessels |
| MX2020005651A (es) * | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| AU2018379091A1 (en) | 2017-12-08 | 2020-06-25 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
| BR112020011223A2 (pt) | 2017-12-08 | 2020-11-17 | Juno Therapeutics Inc | marcadores fenotípicos para terapia celular e mé-todos relacionados |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| EP3773622A4 (fr) * | 2018-03-27 | 2021-12-01 | American Gene Technologies International Inc. | Méthodes de préparation de lymphocytes génétiquement modifiés |
| US12173317B2 (en) | 2018-03-28 | 2024-12-24 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector T cells |
| WO2019217753A1 (fr) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Procédés de production de lymphocytes infiltrant les tumeurs et leurs utilisations en immunothérapie |
| JP7584299B2 (ja) | 2018-05-23 | 2024-11-15 | ナショナル ユニバーシティ オブ シンガポール | T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現 |
| CN110643577A (zh) * | 2018-06-26 | 2020-01-03 | 深圳市北科生物科技有限公司 | 基于机械臂的全自动细胞培养方法及其系统 |
| CN112805378A (zh) | 2018-08-09 | 2021-05-14 | 朱诺治疗学股份有限公司 | 用于评估整合核酸的方法 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| CA3113125A1 (fr) | 2018-09-28 | 2020-04-02 | Octane Biotech Inc. | Separation magnetique |
| WO2020089343A1 (fr) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Procédés de sélection et de stimulation de cellules et appareil associé |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| US20210393691A1 (en) | 2018-11-06 | 2021-12-23 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| EP4427810A3 (fr) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Procédés de traitement utilisant une thérapie cellulaire adoptive |
| KR20210110811A (ko) | 2018-11-30 | 2021-09-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법 |
| EP3898932A4 (fr) | 2018-12-21 | 2022-08-03 | Octane Biotech Inc. | Carrousel pour unités de production biologique modulaires |
| JP7598864B2 (ja) | 2018-12-21 | 2024-12-12 | ロンザ ウォーカーズヴィル,インコーポレーテッド | ウイルスベクターの自動産生方法 |
| TWI732357B (zh) * | 2018-12-27 | 2021-07-01 | 財團法人工業技術研究院 | 細胞培養裝置及方法 |
| US12590292B2 (en) | 2019-01-07 | 2026-03-31 | Children's National Medical Center | Targeted T-cell therapy for treatment of multiple myeloma |
| CN113365654A (zh) * | 2019-01-29 | 2021-09-07 | Gpb科学有限公司 | 具有改进的生产和治疗特征的细胞群 |
| SG11202108473XA (en) | 2019-02-08 | 2021-09-29 | Lonza Walkersville Inc | Cell concentration methods and devices for use in automated bioreactors |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| DE102019108125B4 (de) * | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020198299A1 (fr) * | 2019-03-26 | 2020-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions et procédés de caractérisation et de traitement de la maladie d'alzheimer |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| CA3140873A1 (fr) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Composes cyano-cyclobutyle pour l'inhibition de cbl-b et leurs utilisations |
| WO2020236850A1 (fr) * | 2019-05-20 | 2020-11-26 | Immunovalent Therapeutics Inc. | Dispositifs en phase solide et méthodes d'utilisation pour la purification et la quantification de leucocytes spécifiques de tissu |
| SG11202113356XA (en) | 2019-06-12 | 2021-12-30 | Juno Therapeutics Inc | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
| CN110358734B (zh) * | 2019-06-13 | 2020-08-25 | 首都医科大学宣武医院 | 以Tcm为主要效应成分的CAR-T制备方法及其应用 |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법 |
| CN114600172A (zh) | 2019-08-30 | 2022-06-07 | 朱诺治疗学股份有限公司 | 用于将细胞分类的机器学习方法 |
| EP4048773A4 (fr) | 2019-10-24 | 2024-01-03 | Octane Biotech Inc. | Chambre de culture cellulaire présentant des surfaces de contact cellulaire améliorées |
| MX2022005145A (es) | 2019-10-30 | 2022-06-29 | Juno Therapeutics Gmbh | Dispositivos de estimulación y/o selección celular y método de uso. |
| US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| JP2023501443A (ja) | 2019-11-11 | 2023-01-18 | ロンザ ウォーカーズヴィル,インコーポレーテッド | 自動化された細胞処理のための品質制御方法 |
| EP4070097A1 (fr) | 2019-12-06 | 2022-10-12 | Juno Therapeutics, Inc. | Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b |
| CA3158269A1 (fr) * | 2020-01-10 | 2021-07-15 | Yonatan LEVINSON | Appareil de filtration et procede de purification de processus biologiques et de populations de cellules |
| US20230071910A1 (en) | 2020-01-24 | 2023-03-09 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| CA3169672A1 (fr) | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Compositions de lymphocytes t a recepteur antigenique chimerique dirige contre cd19 et procedes et utilisations associes |
| JP2023519099A (ja) | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用 |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| AU2021262748A1 (en) | 2020-04-27 | 2022-12-01 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting CD127 and use thereof |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| KR20230022868A (ko) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 |
| KR102594083B1 (ko) | 2020-07-07 | 2023-10-25 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| JP2023546534A (ja) * | 2020-10-12 | 2023-11-02 | ライフ・テクノロジーズ・アクシェセルスカプ | 生体細胞と共に使用するための磁性粒子処理システム及び関連する方法 |
| US12415982B2 (en) * | 2020-10-23 | 2025-09-16 | Applied Materials, Inc. | Automated closed system for cell therapy manufacturing |
| WO2022133030A1 (fr) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2 |
| JP2023554395A (ja) | 2020-12-17 | 2023-12-27 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療 |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US20240168012A1 (en) | 2021-03-22 | 2024-05-23 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
| EP4330367A1 (fr) * | 2021-04-29 | 2024-03-06 | Univercells Technologies SA | Systèmes et procédés pour la production et la purification en continu de produits biologiques |
| CN117916256A (zh) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | 用于刺激和转导t细胞的方法 |
| CN113388042B (zh) * | 2021-06-28 | 2022-02-01 | 北京鼎成肽源生物技术有限公司 | 一种重组蛋白、重组表达载体、重组细胞和nk细胞激活磁珠及其制备方法和应用 |
| EP4381050A4 (fr) * | 2021-08-06 | 2025-10-08 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Procédés de fabrication de lymphocytes t |
| US11859166B2 (en) * | 2021-08-17 | 2024-01-02 | Jgc Japan Corporation | Calculation device, control device, culture system, and method for designing culture system |
| CN117659145B (zh) * | 2022-02-14 | 2024-08-02 | 西南大学 | 链霉亲和素第27位丝氨酸突变的突变蛋白s27v及其应用 |
| CN114507274B (zh) * | 2022-02-14 | 2023-08-25 | 西南大学 | 可逆结合生物素的链霉亲和素突变蛋白及其应用 |
| CN119095950A (zh) * | 2022-04-28 | 2024-12-06 | 生物细胞再生有限公司 | 用于分离靶细胞的方法 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023225569A1 (fr) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Fabrication de particules virales |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2023230581A1 (fr) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Procédés de fabrication de thérapies par lymphocytes t |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Cd19標的car t細胞のセカンドライン治療のための処置方法 |
| KR20250120449A (ko) | 2022-11-04 | 2025-08-08 | 우모자 바이오파마 인코포레이티드 | 폴리뉴클레오티드 구축물 및 관련 바이러스 벡터 및 방법 |
| US20260176651A1 (en) | 2022-11-04 | 2026-06-25 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| WO2024100604A1 (fr) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Procédés de fabrication de cellules immunitaires modifiées |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| US20260232729A1 (en) | 2023-02-03 | 2026-08-13 | C3S2 Gmbh | Methods for non-viral manufacturing of engineered immune cells |
| WO2024182516A1 (fr) | 2023-02-28 | 2024-09-06 | Juno Therapeutics, Inc. | Thérapie cellulaire pour le traitement de maladies auto-immunes systémiques |
| CN116640192B (zh) * | 2023-04-12 | 2024-08-02 | 西南大学 | 链霉亲和素突变体StrepTactin的Y43A突变蛋白及其应用 |
| KR20250169631A (ko) | 2023-04-18 | 2025-12-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정 |
| WO2024226858A1 (fr) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Procédés de fabrication de vecteurs viraux |
| WO2024238153A1 (fr) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Administration lentivirale de récepteurs antigéniques chimériques anti-cd20 |
| EP4716851A2 (fr) | 2023-05-23 | 2026-04-01 | Juno Therapeutics, Inc. | Marqueurs d'activation de lymphocytes t et procédé d'évaluation de l'activation de lymphocytes t |
| WO2025011609A1 (fr) | 2023-07-11 | 2025-01-16 | 重庆精准生物技术有限公司 | Procédé de préparation de produit de traitement cellulaire et son utilisation |
| AU2024350024A1 (en) * | 2023-09-25 | 2026-04-16 | The Cleveland Clinic Foundation | Enriched t-cell populations |
| US20250215382A1 (en) * | 2023-12-31 | 2025-07-03 | Trenchant BioSystems, Inc. | Functionally closed cell processing system |
| WO2025231174A1 (fr) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Fabrication de particules virales |
| WO2025235604A1 (fr) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Protéine de fusion destinée à être utilisée en tant qu'engageur de cellules immunitaires |
| US20250345431A1 (en) | 2024-05-10 | 2025-11-13 | Juno Therapeutics, Inc. | Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy |
| WO2026020055A2 (fr) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées |
| WO2026050426A2 (fr) | 2024-08-28 | 2026-03-05 | Juno Therapeutics, Inc. | Thérapie cellulaire par récepteur antigénique chimérique dirigé contre cd19 pour le traitement de maladies auto-immunes et neurologiques |
| WO2026128753A2 (fr) | 2024-12-12 | 2026-06-18 | Juno Therapeutics, Inc. | Procédés d'évaluation de la prolifération cellulaire de compositions cellulaires |
| WO2026143065A1 (fr) | 2024-12-23 | 2026-07-02 | Umoja Biopharma, Inc. | Construction polynucléotidique pour l'expression d'un récepteur antigénique chimérique et vecteurs viraux et méthodes associés |
| WO2026143070A1 (fr) | 2024-12-23 | 2026-07-02 | Umoja Biopharma, Inc. | Constructions de transgènes de récepteur synthétique activé par la rapamycine améliorée |
| WO2026147854A1 (fr) * | 2024-12-31 | 2026-07-09 | Medtherapy Biotechnology Inc. | Procédés d'amélioration de l'efficacité d'une préparation de cellules car+ |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| CA2164226C (fr) | 1993-06-04 | 2011-02-08 | Carl H. June | Methodes pour stimuler de facon selective la proliferation de cellules t |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1997011183A1 (fr) | 1995-04-11 | 1997-03-27 | Trustees Of Boston University | Proteines mutantes de streptavidine |
| US5801115A (en) | 1995-09-05 | 1998-09-01 | Kataleuna Gmbh | Catalyst composition and methods for using and preparing same |
| US5773224A (en) * | 1996-02-12 | 1998-06-30 | Grandics; Peter | Immunoselection system for cell elution |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
| WO2000014257A1 (fr) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6664042B1 (en) | 1999-01-26 | 2003-12-16 | Cornell Research Foundation, Inc. | Determining viral load in double negative T cells |
| CA2410510A1 (fr) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation |
| US7446179B2 (en) | 2000-11-07 | 2008-11-04 | City Of Hope | CD19-specific chimeric T cell receptor |
| EP1227321A1 (fr) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Purification fonctionelle de lymphocytes T antigène-spécifiques par marquage réversible aux multimères MHC |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US8076452B2 (en) | 2002-03-01 | 2011-12-13 | Erdmann Volker A | Streptavidin-binding peptide |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
| EP1569510B1 (fr) | 2002-09-27 | 2011-11-02 | The General Hospital Corporation | Dispositif microfluidique pour la separation de cellules et utilisations de ce dispositif |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| EP1641911A2 (fr) | 2003-05-02 | 2006-04-05 | Insception Bioscience, Inc. | Appareil et procedes pour l'amplification du nombre de cellules sanguines souche |
| US7943393B2 (en) | 2003-07-14 | 2011-05-17 | Phynexus, Inc. | Method and device for extracting an analyte |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗cd19抗体 |
| US20080050795A1 (en) | 2003-11-20 | 2008-02-28 | Biosensor Applications Sweden Ab | Mixture Of At Least Two Different Antibodies Specific For Predetermined Antigens And Use Of The Mixture |
| SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
| EP1766400B1 (fr) | 2004-06-03 | 2009-04-15 | Meso Scale Technologies, LLC | Methodes destinees a realiser des analyses de sang total |
| JP5255841B2 (ja) | 2004-10-15 | 2013-08-07 | ジェネンコー・インターナショナル・インク | 競合示差スクリーニング |
| EP3530321A1 (fr) | 2004-12-10 | 2019-08-28 | Peter MacCallum Cancer Institute | Procédés et compositions d'immunothérapie adoptive |
| US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
| EP1891113A2 (fr) | 2005-06-02 | 2008-02-27 | AstraZeneca AB | Anticorps diriges contre cd20 et leurs utilisations |
| US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
| WO2007117602A2 (fr) | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation et utilisation de lymphocytes t regulateurs humains |
| US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
| CA2668001C (fr) | 2006-11-02 | 2016-05-03 | Kyowa Medex Co., Ltd. | Methode d'immunodosage d'un composant devant etre mesure dans un echantillon contenant de l'hemoglobine |
| US20080255004A1 (en) | 2006-11-15 | 2008-10-16 | Invitrogen Dynal As | Methods of reversibly binding a biotin compound to a support |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| WO2009003493A2 (fr) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Procédés compilés pour analyser et trier des échantillons |
| JP5588865B2 (ja) | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトcd20に対するヒト抗体及びその使用方法 |
| EP2520643B8 (fr) | 2007-12-07 | 2019-11-27 | Miltenyi Biotec B.V. & Co. KG | Systèmes de traitement d'échantillons et procédés |
| WO2009091826A2 (fr) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions et procédés associés à un récepteur d'antigène chimérique spécifique du cd19 humain (h-car) |
| SG10201704689XA (en) | 2008-01-18 | 2017-07-28 | Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| US9090875B2 (en) | 2008-01-29 | 2015-07-28 | Fred Hutchinson Cancer Research Center | Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
| EP2363501A1 (fr) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Nanocomposites dotés d'une homogénéité améliorée |
| EP2601521B1 (fr) | 2010-08-06 | 2018-05-02 | Ludwig-Maximilians-Universität München | Identification d'antigènes cibles de lymphocytes t |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG190937A1 (en) | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
| WO2012081650A1 (fr) | 2010-12-16 | 2012-06-21 | 株式会社明治 | Agent pour l'atténuation d'une hypersensibilité retardée |
| WO2012129514A1 (fr) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Méthodes et compositions pour une immunothérapie cellulaire |
| SI2726600T1 (sl) | 2011-07-01 | 2017-07-31 | Amgen Inc. | Sesalska celična kultura |
| ES2682750T5 (en) | 2011-07-18 | 2025-02-04 | Iba Lifesciences Gmbh | Method of reversibly staining a target cell |
| US9353161B2 (en) * | 2011-09-13 | 2016-05-31 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
| WO2013062365A2 (fr) * | 2011-10-26 | 2013-05-02 | 국립암센터 | Lymphocyte t transfecté par un gène ctla4 mutant et composition en contenant pour immunothérapie anticancéreuse |
| EP2814846B1 (fr) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
| WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
| SG11201404991YA (en) | 2012-02-23 | 2014-09-26 | Stage Cell Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| CN110241086A (zh) * | 2012-06-11 | 2019-09-17 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| WO2013192294A1 (fr) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Thérapies cellulaires pour le traitement et la prévention de cancers et d'autres troubles du système immunitaire |
| MX382772B (es) | 2012-07-13 | 2025-03-11 | Univ Pennsylvania | Composición para usarse para prevenir o retardar el rechazo de trasplante de un tejido u órgano trasplantado en un sujeto. |
| KR20210149195A (ko) | 2012-07-13 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 형질도입된 t 세포의 투여 적합성을 평가하는 방법 |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| EP3919079A1 (fr) | 2012-09-07 | 2021-12-08 | Genentech, Inc. | Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20 |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US9599590B2 (en) | 2012-10-12 | 2017-03-21 | Sage Science, Inc. | Side-eluting molecular fractionator |
| EP2920204B1 (fr) | 2012-11-16 | 2019-09-18 | IBA GmbH | Mutéines de streptavidine et procédés d'utilisation associés |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| EP3789487A1 (fr) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Génération efficace de lymphocytes t ciblant une tumeur dérivés de cellules souches pluripotentes |
| EP2997134B1 (fr) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car) |
| CN103305464B (zh) * | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| RS62471B1 (sr) | 2014-04-16 | 2021-11-30 | Juno Therapeutics Gmbh | Metode, kompleti i uređaji za proširenje populacije ćelija |
| US20170158749A1 (en) | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| IL292038B2 (en) * | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| JP6661544B2 (ja) | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
| CN106456670B (zh) | 2014-04-25 | 2020-01-07 | 蓝鸟生物公司 | 制备过继性细胞疗法的改善方法 |
| EP3166968B1 (fr) | 2014-05-02 | 2021-09-22 | The Trustees of the University of Pennsylvania | Compositions de récepteurs d'auto-anticorps chimériques et procédés afférents |
| WO2016019300A1 (fr) | 2014-07-31 | 2016-02-04 | Novartis Ag | Sous-ensemble optimisé de lymphocytes t contenant un récepteur d'antigène chimère |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| US10131901B2 (en) | 2014-10-15 | 2018-11-20 | Sage Science, Inc. | Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| JP6740234B2 (ja) | 2014-11-05 | 2020-08-12 | ジュノー セラピューティクス インコーポレイテッド | 形質導入および細胞プロセシングのための方法 |
| EP3227323B1 (fr) | 2014-12-03 | 2020-08-05 | Juno Therapeutics, Inc. | Procédés et compositions pour thérapie cellulaire adoptive |
| CN107429253B (zh) | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| DE102015205759A1 (de) | 2015-03-31 | 2016-10-06 | Henkel Ag & Co. Kgaa | Mittel für keratinhaltige Fasern, enthaltend mindestens ein Copolymer auf Basis von Vinylpyrrolidon und mindestens ein Copolymer aus Basis von Acrylaten |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| HK1256130A1 (zh) | 2015-07-21 | 2019-09-13 | City Of Hope | 用於嵌合抗原受体和其他受体的表达的t细胞 |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| EP4339287A3 (fr) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Cellules modifiées et procédés de thérapie |
| MX2018001568A (es) | 2015-08-07 | 2019-04-25 | Seattle Children´S Hospital Dba Seattle Children´S Res Institute | Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos. |
| KR102908806B1 (ko) | 2015-10-22 | 2026-01-07 | 주노 테라퓨틱스 게엠베하 | 세포의 배양 방법 및 이를 위한 키트와 장치 |
| MX2018006789A (es) | 2015-12-03 | 2019-02-13 | Juno Therapeutics Inc | Receptores quimericos modificados y composiciones y metodos relacionados. |
| WO2017156479A1 (fr) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Récepteurs antigéniques chimériques anti-ror1 |
| KR20180125999A (ko) | 2016-03-17 | 2018-11-26 | 메르크 파텐트 게엠베하 | 폴록사머의 정제 방법 |
| AU2017235657B2 (en) | 2016-03-18 | 2022-07-21 | Fred Hutchinson Cancer Center | Compositions and methods for CD20 immunotherapy |
| WO2018106732A1 (fr) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production de cellules modifiées pour une thérapie cellulaire adoptive |
| EP3346001A1 (fr) | 2017-01-06 | 2018-07-11 | TXCell | Population de cellules t régulatrices monospécifiques avec cytotoxicité pour cellules b |
| CN110709700A (zh) | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| CN107723275B (zh) | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| JP7357626B2 (ja) | 2017-11-01 | 2023-10-06 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞の治療用組成物を生成するためのプロセス |
| CN119193493A (zh) | 2017-12-08 | 2024-12-27 | 朱诺治疗学股份有限公司 | 生产工程化t细胞组合物的过程 |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| CA3169672A1 (fr) | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Compositions de lymphocytes t a recepteur antigenique chimerique dirige contre cd19 et procedes et utilisations associes |
| JP2023519099A (ja) | 2020-02-12 | 2023-05-10 | ジュノー セラピューティクス インコーポレイテッド | Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用 |
-
2015
- 2015-04-23 IL IL292038A patent/IL292038B2/en unknown
- 2015-04-23 ES ES23164036T patent/ES2995052T3/es active Active
- 2015-04-23 SG SG11201608862SA patent/SG11201608862SA/en unknown
- 2015-04-23 US US15/305,337 patent/US11400115B2/en active Active
- 2015-04-23 AU AU2015249554A patent/AU2015249554B2/en active Active
- 2015-04-23 WO PCT/US2015/027401 patent/WO2015164675A1/fr not_active Ceased
- 2015-04-23 EP EP24194366.1A patent/EP4450615A3/fr active Pending
- 2015-04-23 EP EP15721094.9A patent/EP3134514B1/fr active Active
- 2015-04-23 JP JP2017507920A patent/JP6759187B2/ja active Active
- 2015-04-23 IL IL313845A patent/IL313845A/en unknown
- 2015-04-23 BR BR112016024579A patent/BR112016024579A2/pt not_active Application Discontinuation
- 2015-04-23 PL PL23164036.8T patent/PL4219687T3/pl unknown
- 2015-04-23 ES ES15721094T patent/ES2759260T3/es active Active
- 2015-04-23 KR KR1020167032823A patent/KR102447958B1/ko active Active
- 2015-04-23 MA MA051794A patent/MA51794A/fr unknown
- 2015-04-23 CA CA2946312A patent/CA2946312A1/fr not_active Abandoned
- 2015-04-23 CN CN202110191715.XA patent/CN113046312A/zh active Pending
- 2015-04-23 EP EP23164036.8A patent/EP4219687B1/fr active Active
- 2015-04-23 EP EP19197801.4A patent/EP3647412A1/fr not_active Withdrawn
- 2015-04-23 RU RU2016145424A patent/RU2763795C2/ru active
- 2015-04-23 PT PT231640368T patent/PT4219687T/pt unknown
- 2015-04-23 CN CN202110191749.9A patent/CN113046321A/zh active Pending
- 2015-04-23 KR KR1020227032825A patent/KR20220136455A/ko not_active Ceased
- 2015-04-23 FI FIEP23164036.8T patent/FI4219687T3/fi active
- 2015-04-23 MX MX2016013747A patent/MX382541B/es unknown
- 2015-04-23 CN CN201580034318.4A patent/CN106459917B/zh active Active
- 2015-04-23 DK DK23164036.8T patent/DK4219687T3/da active
- 2015-04-23 MA MA039867A patent/MA39867A/fr unknown
- 2015-04-23 KR KR1020247033230A patent/KR20240149454A/ko active Pending
-
2016
- 2016-10-19 MX MX2021005625A patent/MX2021005625A/es unknown
- 2016-10-21 PH PH12016502112A patent/PH12016502112A1/en unknown
- 2016-10-23 IL IL24845116A patent/IL248451B/en active IP Right Grant
- 2016-10-23 SA SA516380118A patent/SA516380118B1/ar unknown
-
2019
- 2019-09-18 IL IL269440A patent/IL269440B/en active IP Right Grant
-
2020
- 2020-06-01 JP JP2020095186A patent/JP7181910B2/ja active Active
-
2021
- 2021-02-09 IL IL280743A patent/IL280743B/en unknown
- 2021-07-27 AU AU2021209195A patent/AU2021209195B2/en active Active
- 2021-08-23 JP JP2021135398A patent/JP7503035B2/ja active Active
-
2022
- 2022-06-27 US US17/850,875 patent/US20230090176A1/en active Pending
-
2023
- 2023-02-08 US US18/166,447 patent/US12208137B2/en active Active
-
2024
- 2024-03-19 JP JP2024043330A patent/JP7675243B2/ja active Active
- 2024-04-12 AU AU2024202424A patent/AU2024202424A1/en active Pending
- 2024-12-16 US US18/983,137 patent/US12296010B2/en active Active
-
2025
- 2025-01-17 US US19/029,968 patent/US20250152712A1/en active Pending
- 2025-01-17 US US19/030,056 patent/US20250161450A1/en active Pending
- 2025-01-17 US US19/030,019 patent/US20250161449A1/en active Pending
- 2025-04-25 JP JP2025072785A patent/JP2025108747A/ja active Pending
- 2025-08-27 US US19/312,145 patent/US20250387482A1/en active Pending
-
2026
- 2026-03-17 US US19/570,013 patent/US20260216332A1/en active Pending
- 2026-03-17 US US19/570,016 patent/US20260191959A1/en active Pending
- 2026-03-17 US US19/570,009 patent/US20260216331A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005625A (es) | Metodos para aislar, cultivar y dise?ar geneticamente poblaciones de celulas inmunes para terapia adoptiva. | |
| BR112015019950A2 (pt) | Método para gerar linhagem de células-tronco embrionárias (es) de rato, e, cultura in vitro | |
| EP4289944A3 (fr) | Procédé de préparation de lymphocytes t génétiquement modifiés exprimant un récepteur antigénique chimérique | |
| EP4530350A3 (fr) | Technologie de torchère améliorée (flow cytoméro attenued reporter expression) pour tri en vrac rapide | |
| MX2021008142A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
| WO2016090178A3 (fr) | Procédés de production d'exosomes dans des conditions de culture à teneur en oxygène réduite | |
| AU2018271755A1 (en) | Method for culturing natural killer cell, using transformed T cell | |
| ZA201606933B (en) | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair | |
| BR112017007770A2 (pt) | cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc. | |
| MX2019007840A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| EA202091407A1 (ru) | Состав бессывороточной среды для культивирования клеток и способы его применения | |
| SG10201807208RA (en) | Viral resistant cells and uses thereof | |
| MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
| EP4148121A3 (fr) | Perfusion à pilotage cellulaire en culture continue | |
| MX2020009670A (es) | Metodos de cultivo por perfusion y usos de los mismos. | |
| MY181513A (en) | Cell culture compositions and methods for polypeptide production | |
| EA201991976A1 (ru) | Метаболически оптимизированная клеточная культура | |
| EA200501774A1 (ru) | Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции | |
| EP2588594A4 (fr) | Procédés de culture de cellules indifférenciées à l'aide de compositions à libération prolongée | |
| MX2015011781A (es) | Medio de cultivo celular y metodos de produccion de anticuerpos. | |
| IL246525B (en) | Pomegranate derived cell culture and methods for preparing and using the same | |
| NZ708061A (en) | Methods for generating genetically superior animals | |
| MX2021001981A (es) | Metodos para preparar un poloxamero para usar en medio de cultivo celular. | |
| MX2022000516A (es) | Metodos relacionados con celulas pluripotentes. | |
| MY199770A (en) | Method for culturing cord blood-derived natural killer cells using transformed t cells |